<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02571751</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol Approval No. 534</org_study_id>
    <nct_id>NCT02571751</nct_id>
  </id_info>
  <brief_title>Open-label, Multi-center Trial to Evaluate Safety and Efficacy of Cohesive Silicone Gel-Filled Breast Implants UNIGEL®</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sewoon Medical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sewoon Medical Co., Ltd</source>
  <brief_summary>
    <textblock>
      Open-label, Multi-center, Clinical trial to Evaluate Safety and Efficacy of Cohesive
      Gel-Filled Breast Implants UNIGEL® Targeting of Women from 22 to 60 Aged with regard to
      Augmentation Mammaplasty for Purpose of Cosmetic Surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>a rate of rupture of 4%</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>a rate of capsular contracture of 10%</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Analysis of rupture or capsular contracture events</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in nipple sensitivity</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a rate of adverse evnets</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in chest, bust and under bust circumference</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36(Short Form (36) Health Survey ), Evaluation of quality of life</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>Breast Augmentation</condition>
  <arm_group>
    <arm_group_label>Breast Augmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>UNIGEL Silicone Gel-Filled Breast Implant</intervention_name>
    <arm_group_label>Breast Augmentation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has given written informed consent to entry

          -  Female, 22 years to 60 years

          -  Breast augmentation(cosmetic surgery) is for following subjects

               -  Who is not content with breast size and shape

               -  Who has congenital asymmetrical deformity

          -  subject who agree to MRI scan during the trial

          -  subject who agree to visit to hospital according to schedule specified in the protocol
             during the entire period of the trial

        Exclusion Criteria:

          -  Pregnant or lactating women and women of childbearing age

          -  Subject who has operation history of breast augmentation or reconstruction

          -  Subject who has fibrocystic Breast Disease coming up for precancerous lesion not
             accompanied with subcutaneous mastectomy

          -  Subject who has breast cancer or prodromal phase and no proper treatment.

          -  Subject who is diagnosed with Breast Imaging-Reporting and Data System(BI-RADS)
             category 3 under breast ultrasonography.

          -  Subject who has uncontrolled active infectious disease or abscess

          -  Autoimmune disease

          -  Diabetes mellitus

          -  Keloidosis

          -  Subject who cannot take general anesthesia due to abnormal blood or ECG results.

          -  Subject who is not appropriate for breast augmentation due to damaged tissue or blood
             vessel or ulcer

          -  Subject who has metal materials in a body such as ventricular assist system or
             cerebral aneurysm clips, or has claustrophobia (not suitable for MRI SCAN)

          -  Physically/mentally disabled subject that may disturb understanding and cooperation
             for the trial.

          -  Any other conditions that may interfere with correct assessment of the trial.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>NaRae Lee</last_name>
    <email>r1457@snubh.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NaRae Lee</last_name>
      <phone>+82-31-787-8252</phone>
      <email>r1457@snubh.org</email>
    </contact>
    <investigator>
      <last_name>ChanYeong Heo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2015</study_first_submitted>
  <study_first_submitted_qc>October 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2015</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

